These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers. Wu W; Grohganz H; Rades T; Löbmann K Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568 [TBL] [Abstract][Full Text] [Related]
8. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems. Wu W; Löbmann K; Rades T; Grohganz H Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703 [TBL] [Abstract][Full Text] [Related]
9. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems. Wu W; Ueda H; Löbmann K; Rades T; Grohganz H Eur J Pharm Biopharm; 2018 Oct; 131():25-32. PubMed ID: 30040997 [TBL] [Abstract][Full Text] [Related]
10. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816 [TBL] [Abstract][Full Text] [Related]
11. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems. Wu W; Wang Y; Löbmann K; Grohganz H; Rades T Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075 [TBL] [Abstract][Full Text] [Related]
12. Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers. Shete S; Reddy SC; Lakshman YD; Vullendula SKA; Mehta CH; Nayak UY; Dengale S Int J Pharm; 2021 Oct; 608():121119. PubMed ID: 34560205 [TBL] [Abstract][Full Text] [Related]
13. Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin. Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS Molecules; 2015 Oct; 20(10):19571-87. PubMed ID: 26516832 [TBL] [Abstract][Full Text] [Related]
14. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation. Amharar Y; Curtin V; Gallagher KH; Healy AM Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139 [TBL] [Abstract][Full Text] [Related]
15. In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - A proof of concept study. Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS Eur J Pharm Biopharm; 2018 Dec; 133():151-160. PubMed ID: 30339888 [TBL] [Abstract][Full Text] [Related]
17. Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review. Nugrahani I; Jessica MA Molecules; 2021 May; 26(11):. PubMed ID: 34071731 [TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions. Xiang TX; Anderson BD J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486 [TBL] [Abstract][Full Text] [Related]
19. Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine. Ueda H; Wu W; Löbmann K; Grohganz H; Müllertz A; Rades T Mol Pharm; 2018 May; 15(5):2036-2044. PubMed ID: 29630842 [TBL] [Abstract][Full Text] [Related]
20. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers. Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]